BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 34434610)

  • 21. [Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma].
    Ge J; Zhao TT; Wan CY; Xia JY; Guo SY; Yu MX; Chen J; Wang Y; Xu KL; Li ZY
    Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):733-738. PubMed ID: 34753227
    [No Abstract]   [Full Text] [Related]  

  • 22. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.
    Lee L; Draper B; Chaplin N; Philip B; Chin M; Galas-Filipowicz D; Onuoha S; Thomas S; Baldan V; Bughda R; Maciocia P; Kokalaki E; Neves MP; Patel D; Rodriguez-Justo M; Francis J; Yong K; Pule M
    Blood; 2018 Feb; 131(7):746-758. PubMed ID: 29284597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.
    Duan D; Wang K; Wei C; Feng D; Liu Y; He Q; Xu X; Wang C; Zhao S; Lv L; Long J; Lin D; Zhao A; Fang B; Jiang J; Tang S; Gao J
    Front Immunol; 2021; 12():609421. PubMed ID: 33767695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors.
    Metelo AM; Jozwik A; Luong LA; Dominey-Foy D; Graham C; Attwood C; Inam S; Dunlop A; Sanchez K; Cuthill K; Rice C; Streetly M; Bentley T; Boldajipour B; Sommer C; Sasu B; Benjamin R
    Cancer Res Commun; 2022 Mar; 2(3):158-171. PubMed ID: 36874402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
    Ferment B; Arnulf B
    Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma.
    Fernández de Larrea C; Staehr M; Lopez AV; Ng KY; Chen Y; Godfrey WD; Purdon TJ; Ponomarev V; Wendel HG; Brentjens RJ; Smith EL
    Blood Cancer Discov; 2020 Sep; 1(2):146-154. PubMed ID: 33089218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma.
    Larson RC; Kann MC; Graham C; Mount CW; Castano AP; Lee WH; Bouffard AA; Takei HN; Almazan AJ; Scarfó I; Berger TR; Schmidts A; Frigault MJ; Gallagher KME; Maus MV
    Nat Commun; 2023 Nov; 14(1):7509. PubMed ID: 37980341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Targeting BCMA in multiple myeloma using chimeric antigen receptor-engineered T cells].
    Zhong MJ; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):804-811. PubMed ID: 31775477
    [No Abstract]   [Full Text] [Related]  

  • 29. BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma.
    Lu Q; Li H; Wu Z; Zhu Z; Zhang Z; Yang D; Tong A
    J Nanobiotechnology; 2024 May; 22(1):279. PubMed ID: 38783333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy].
    Cui R; Li P; Li Q; Mu J; Jiang YL; Jiang YY; Deng Q
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):502-507. PubMed ID: 34384157
    [No Abstract]   [Full Text] [Related]  

  • 31. Cytotoxicity and exhaustion markers of chimeric antigen receptor T cells targeting BCMA in multiple myeloma cell lines between patients and healthy donors.
    Prasongtanakij S; Preedagasamzin S; Jittorntrum B; Anurathapan U; Puavilai T; Niparuck P; Chantrathammachart P; Piyajaroenkij T; Uaesoontrachoon K; Uchibori R; Ozawa K; Ohmine K; Hongeng S
    Eur J Haematol; 2024 Feb; 112(2):248-256. PubMed ID: 37222081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.
    Choi T; Kang Y
    Pharmacol Ther; 2022 Apr; 232():108007. PubMed ID: 34582835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
    Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
    Front Immunol; 2021; 12():755866. PubMed ID: 34777368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BCMA CAR-T cells in multiple myeloma-ready for take-off?
    Scheller L; Tebuka E; Rambau PF; Einsele H; Hudecek M; Prommersberger SR; Danhof S
    Leuk Lymphoma; 2024 Feb; 65(2):143-157. PubMed ID: 37997705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [CAR-T therapy for multiple myeloma].
    Ri M
    Rinsho Ketsueki; 2023; 64(11):1456-1464. PubMed ID: 38072434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Directed targeting of B-cell maturation antigen-specific CAR T cells by bioinformatic approaches: From in-silico to in-vitro.
    Moazzeni A; Kheirandish M; Khamisipour G; Rahbarizadeh F
    Immunobiology; 2023 May; 228(3):152376. PubMed ID: 37058845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
    Tai YT; Anderson KC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
    [No Abstract]   [Full Text] [Related]  

  • 38. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.
    Lee H; Ahn S; Maity R; Leblay N; Ziccheddu B; Truger M; Chojnacka M; Cirrincione A; Durante M; Tilmont R; Barakat E; Poorebrahim M; Sinha S; McIntyre J; M Y Chan A; Wilson H; Kyman S; Krishnan A; Landgren O; Walter W; Meggendorfer M; Haferlach C; Haferlach T; Einsele H; Kortüm MK; Knop S; Alberge JB; Rosenwald A; Keats JJ; Rasche L; Maura F; Neri P; Bahlis NJ
    Nat Med; 2023 Sep; 29(9):2295-2306. PubMed ID: 37653344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
    Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
    J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies.
    Zhang X; Zhang H; Lan H; Wu J; Xiao Y
    Front Immunol; 2023; 14():1101495. PubMed ID: 36891310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.